An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease (GEMINI LTS)
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Sponsor: Takeda
A PHASE3 clinical study on Crohn's Disease and Ulcerative Colitis, this trial is completed. The trial is conducted by Takeda and has accumulated 11 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Mar 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE3
First recorded
May 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .